Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03916419 · ClinicalTrials.gov registry record · Phase 2
Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03916419 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 26 participants.
The verdict
NCT03916419, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small cell lung cancer (NSCLC), this prospective, single-arm Phase II clinical trial with safety lead-in will test the feasibility and outcomes of this approach.
Interventions
- BIOLOGICAL Durvalumab
- DRUG Paclitaxel
- RADIATION Radiation therapy
- DRUG Carboplatin AUC
- DEVICE ViewRay MR-Linear Accelerator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2025-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03916419
The ClinicalTrials.gov registry entry for NCT03916419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Durvalumab is the first listed.
NCT03916419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03916419 about?
NCT03916419 is a clinical study titled "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer". Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally advanced non-small c...
What is the current status of trial NCT03916419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2019-06-20. Estimated completion is 2025-09-28.
What interventions are being tested in trial NCT03916419?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Paclitaxel (DRUG), Radiation therapy (RADIATION), Carboplatin AUC (DRUG), ViewRay MR-Linear Accelerator (DEVICE).
Who is sponsoring clinical trial NCT03916419?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.